New Research on Niacin 2015 link
Conclusions—
In statin-treated men with type 2 diabetes mellitus, Extended Release Niacin decreased plasma Lp(a) concentrations by decreasing the production of apo(a) and Lp(a)-apoB-100.
Extended Release Niacin also decreased the concentrations of apoB-100–containing lipoproteins by decreasing VLDL production and the transport of these particles down the VLDL to LDL cascade.
Our study provides further mechanistic insights into the lipid-regulating effects of Extended Release Niacin.
Conclusions—
In statin-treated men with type 2 diabetes mellitus, Extended Release Niacin decreased plasma Lp(a) concentrations by decreasing the production of apo(a) and Lp(a)-apoB-100.
Extended Release Niacin also decreased the concentrations of apoB-100–containing lipoproteins by decreasing VLDL production and the transport of these particles down the VLDL to LDL cascade.
Our study provides further mechanistic insights into the lipid-regulating effects of Extended Release Niacin.
No comments:
Post a Comment